Skip to content
HowShorted

REGENXBIO Inc. short interest in 2023

In 2023, REGENXBIO Inc.'s disclosed short interest ran from 7.06% of shares outstanding on 13 Jan 2023 to 9.44% on 29 Dec 2023, a change of +2.38 percentage points. The year's high was 11.18% on 15 May 2023 and its low 7.06% on 13 Jan 2023, averaging 9.72% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 18.99 days on 31 Jul 2023. Full history: REGENXBIO Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for REGENXBIO Inc. in 2023

2023 in figures

Start of year
7.06% (13 Jan 2023)
End of year
9.44% (29 Dec 2023)
Change
+2.38 pp
High
11.18% (15 May 2023)
Low
7.06% (13 Jan 2023)
Average
9.72%
Highest days to cover
18.99 (31 Jul 2023)
SEC filings marked
8

Every report in 2023

REGENXBIO Inc. short interest in 2023
SettlementShort interestDays to coverFilings since previous
13 Jan 20237.06%9.70
31 Jan 20237.58%10.38
15 Feb 20238.62%9.41
28 Feb 20239.64%11.2210-K filed, results (8-K)
15 Mar 202310.26%8.65
31 Mar 202310.44%8.53
14 Apr 202310.79%10.42
28 Apr 202310.91%16.15
15 May 202311.18%10.8910-Q filed, results (8-K)
31 May 202311.03%10.20
15 Jun 202310.45%13.01
30 Jun 202310.30%8.88
14 Jul 202310.42%12.58
31 Jul 202310.20%18.99
15 Aug 20239.91%11.9510-Q filed, results (8-K)
31 Aug 20239.79%13.66
15 Sep 20239.96%11.74
29 Sep 20239.10%11.35
13 Oct 20239.67%10.06
31 Oct 20239.41%9.92
15 Nov 20239.23%5.7710-Q filed, results (8-K)
30 Nov 20238.83%9.70
15 Dec 20239.06%9.07
29 Dec 20239.44%7.35

See also: REGENXBIO Inc.'s full history · most shorted US stocks of 2023 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.